ProQR Announces Annual General Meeting of Shareholders to be Held June 3, 2025

Company Overview - ProQR Therapeutics N.V. is focused on developing transformative RNA therapies using its proprietary Axiomer™ RNA editing technology platform [1][4] - The company aims to create a new class of medicines targeting both rare and prevalent diseases with unmet medical needs [4] Axiomer™ Technology - Axiomer™ is a next-generation RNA base editing technology that allows for specific single nucleotide changes in RNA [3][4] - The technology utilizes the human cell's own ADAR (Adenosine Deaminase Acting on RNA) machinery to convert Adenosine (A) to Inosine (I), which is then translated as Guanosine (G), effectively correcting disease-causing mutations [3] Upcoming Events - ProQR will hold its Annual General Meeting (AGM) on June 3, 2025, at 15:30 CEST in Amsterdam, Netherlands [1] - Relevant documents for the AGM will be available on ProQR's website and the SEC's website [2]